ISOPP CAPhO 2025 Symposium: Transforming GU Cancer Care for Improved Patient Outcomes: The Pharmacist’s Role in Implementing Practice-Changing Data - Merck On-Demand Symposium

The GU oncology treatment landscape is growing increasingly innovative and complex with an increasing number of therapeutic options becoming available for patient treatment, both alone as single agents, as well as in various combinations of multiple agents. While these innovations in care are improving patient outcomes, they also come with patient management complexities that require a team approach to patient management.

Learning Objectives

1. REVIEW and EVALUATE the impact of recent practice changing data in genitourinary (GU) oncology, (RCC), highlighting the implications for treatment and patient care.
2. EXPLAIN and RECOGNIZE actionable strategies for pharmacy professionals to enhance the cancer care experience by optimizing patient management and addressing the unique side effects and needs stemming from novel GU oncology therapies.
3. EXAMINE multidisciplinary collaborative practice models that empower pharmacists to lead in patient care, highlighting real-world examples and best practices that can improve the patient experience and overall care delivery.

Featuring experts Chelsea Normore and Matthew Young. This session covers recent practice-changing data in genitourinary (GU) oncology, with a focus on bladder cancer and renal cell carcinoma (RCC), and its impact on treatment and patient care. It emphasizes actionable strategies for pharmacy professionals to optimize cancer care, manage patients effectively, and address the unique side effects of novel GU oncology therapies. Additionally, it explores multidisciplinary collaborative practice models, presenting real-world examples and best practices that enable pharmacists to lead in patient care and improve overall care delivery.